Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198789 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL3198780 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL2181309 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4527860 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| Hydrochloric Acid SCHEMBL30478389 | 0.98 | GAA (0.42) | GAANFKB1NFKB2RELAEPHX2 | |
| Formic Acid SCHEMBL9046870 | 0.94 | GAA (0.39) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6167830 | 0.93 | GAA (0.41) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6167832 | 0.93 | GAA (0.41) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL5024706 | 0.91 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4643757 | 0.91 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443498-A1 | Isoindoline derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-12281116-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-0230295-B1 | 8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same | KYORIN SEIYAKU KK (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5245037-A | Synthetic bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0443498-A1 | Isoindoline derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-5043450-A | Bactericides | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-27 | — | — | US | disclosed |
| US-4980470-A | 8-alkoxyquinolonecarboxylic acid and salts thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0393400-A1 | Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0208210-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4753953-A | Pyridonecarboxylic acid derivatives and antibacterial pharmaceutical compositions thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0230295-A2 | 8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0208210-A1 | Pyridonecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281116-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | GAA 143/4885NFKB1 3237/4885NFKB2 3001/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | GAA 1009/4885NFKB1 1349/4885NFKB2 878/4885 |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | GAA 143/4885NFKB1 3237/4885NFKB2 3001/4885 |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | ESR1, PGR, GPER1 | GAA 1364/4885NFKB1 192/4885NFKB2 282/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | GAA 192/4885NFKB1 1233/4885NFKB2 1129/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | GAA 2873/4885NFKB1 971/4885NFKB2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.